KCNQ4

Hearing loss company Acousia Therapeutics to present data for lead candidates ACOU085 & ACOU082 at ARO 2023 MidWinter Meeting February 11-15

Retrieved on: 
Thursday, November 24, 2022
Cochlea, Translation, Hearing loss, ABR, Midwinter, Therapy, Ageing, Pharmacology, Cancer, Guinea, Apoptosis, Research, University, Gesellschaft mit beschränkter Haftung, Patient, Pharmaceutical industry, KCNQ4, Otorhinolaryngology

The ACOU085 presentation at the 2023 MidWinter Meeting will focus on preclinical pharmacology data from a guinea pig cisplatin-induced ototoxicity model, which supports the potential of ACOU085 treatment for preventing chemotherapy-induced hearing loss and outer hair cell apoptosis in cancer patients.

Key Points: 
  • The ACOU085 presentation at the 2023 MidWinter Meeting will focus on preclinical pharmacology data from a guinea pig cisplatin-induced ototoxicity model, which supports the potential of ACOU085 treatment for preventing chemotherapy-induced hearing loss and outer hair cell apoptosis in cancer patients.
  • ACOU082 is a proprietary small molecule Kv7.4 developed for oral administration with the potential to both acutely enhance natural hearing and preserve hearing capacity against e.g.
  • Furthermore, ACOU082 also significantly reduced the progression of age-related hearing loss as measured by ABR threshold shifts and compared to a placebo-treated, vehicle control group.
  • The company is dedicated to the identification and development of small molecules for effective prevention and treatment of different etiologies of hearing loss.

Hearing loss company Acousia Therapeutics to present data for lead candidates ACOU085 & ACOU082 at ARO 2023 MidWinter Meeting February 11-15

Retrieved on: 
Thursday, November 24, 2022
Cochlea, Translation, Hearing loss, ABR, Midwinter, Therapy, Ageing, Pharmacology, Cancer, Guinea, Apoptosis, Research, University, Gesellschaft mit beschränkter Haftung, Patient, Pharmaceutical industry, KCNQ4, Otorhinolaryngology

The ACOU085 presentation at the 2023 MidWinter Meeting will focus on preclinical pharmacology data from a guinea pig cisplatin-induced ototoxicity model, which supports the potential of ACOU085 treatment for preventing chemotherapy-induced hearing loss and outer hair cell apoptosis in cancer patients.

Key Points: 
  • The ACOU085 presentation at the 2023 MidWinter Meeting will focus on preclinical pharmacology data from a guinea pig cisplatin-induced ototoxicity model, which supports the potential of ACOU085 treatment for preventing chemotherapy-induced hearing loss and outer hair cell apoptosis in cancer patients.
  • ACOU082 is a proprietary small molecule Kv7.4 developed for oral administration with the potential to both acutely enhance natural hearing and preserve hearing capacity against e.g.
  • Furthermore, ACOU082 also significantly reduced the progression of age-related hearing loss as measured by ABR threshold shifts and compared to a placebo-treated, vehicle control group.
  • The company is dedicated to the identification and development of small molecules for effective prevention and treatment of different etiologies of hearing loss.